Bacteria are winning. Every year, more and more microbes dodge the antibiotics designed to kill them, squirting the drugs out of their cells before the medicines can work. Now, researchers at King's College London have found a way to outsmart that escape route—by chemically redesigning antibiotics so bacteria cannot easily expel them.
The problem is urgent: antimicrobial resistance is rising, yet the number of truly new antibiotics in development remains worryingly low. Most bacteria that develop resistance do so through a cunning mechanism. They deploy molecular pumps, called efflux pumps, that act like tiny security guards, pushing antibiotics out of the cell before the drugs can accumulate to lethal levels. This reduces the antibiotic concentration inside the bacteria, allowing resistant infections to survive and spread.
The new approach, called "Efflux Resistance Breaker" or ERB, represents a shift in how scientists design these life-saving drugs. Instead of combining an antibiotic with a separate chemical that blocks the pumps—a strategy that has had limited success—the King's College team has built resistance-breaking properties directly into the antibiotic molecule itself. The antibiotic is designed to protect itself from being pumped out, remaining inside the bacterial cell at higher concentrations where it can actually kill the pathogen.
"Our work shows that we can redesign antibiotics so they stay inside bacterial cells at higher concentrations and overcome resistance mechanisms that would normally make them ineffective," said Professor Khondaker Miraz Rahman, who led the study published in the Journal of Medicinal Chemistry. "This approach could help us design better new antibiotics, but it could also help revive existing antibiotic classes that bacteria have learned to defeat."
That last point matters enormously. Antibiotics that once saved lives have become useless as bacteria evolved defenses against them. ERB technology offers a path to resurrection, breathing new life into drugs that have been rendered ineffective by years of resistance development.
Professor J. Mark Sutton from the UK Health Security Agency, a key collaborator on the project, emphasized the scale of the problem: "Efflux pumps are a major cause of antibiotic resistance because they reduce the concentration of drug inside the bacterial cell. This study shows that rational chemical design can be used to overcome that problem."
The research provides crucial proof of concept. By maintaining high intracellular antibiotic concentration—keeping the drug inside the bacteria where it belongs—scientists can overcome resistance, even in bacteria that already show reduced susceptibility to existing antibiotics. This is not theoretical; the team has demonstrated that the approach works in practice.
The implications extend far beyond any single drug. The ERB platform offers a general strategy, a framework for designing entire classes of next-generation antibiotics with built-in resilience to efflux-mediated resistance. Researchers now plan to commercialize the technology and advance antibiotics developed using this method toward clinical development, aiming to translate this discovery into new treatment options for drug-resistant infections in the years ahead. In a landscape where antibiotic innovation has stalled, this breakthrough offers a path forward.